NCT06987513 - RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Alcohol Use Disorder (AUD)

Interventions

DRUG

Pemvidutide

Pemvidutide 2.4mg

OTHER

Placebo

Subcutaneous injection

Trial Locations (12)

19104

RECRUITING

Altimmune Clinical Study Site, Philadelphia

22903

RECRUITING

Altimmune Clinical Study Site, Charlottesville

23298

RECRUITING

Altimmune Clinical Study Site, Richmond

29425

RECRUITING

Altimmune Clinical Study Site, Charleston

33912

RECRUITING

Altimmune Clinical Study Site, Fort Myers

34201

RECRUITING

Altimmune Clinical Study Site, University Park

44720

RECRUITING

Altimmune Clinical Study Site, North Canton

74136

RECRUITING

Altimmune Clinical Study Site, Tulsa

80045

RECRUITING

Altimmune Clinical Study Site, Aurora

90038

RECRUITING

Altimmune Clinical Study Site, Los Angeles

06511

RECRUITING

Altimmune Clinical Study Site, New Haven

02923

RECRUITING

Altimmune Clinical Study Site, Providence